Skip to main content
. 2021 Mar 12;12(3):268. doi: 10.1038/s41419-020-03269-0

Fig. 5. Efficacy of WEHI-7326 in cisplatin-refractory patient-derived xenograft mouse models of lung squamous cell carcinoma.

Fig. 5

a, b Tumor growth curve (a) and Kaplan–Meier survival plot (b) of MH792 LUSC PDX recipient male mice treated with either docetaxel (10 mg/kg, i.p.; once) or WEHI-7326 (20 mg/kg, i.v.; twice a week). p(docetaxel) = 0.1131 (ns), p(WEHI-7326) = 0.0002 (***) compared to vehicle control; p-values obtained through Log-rank (Mantel–Cox) test, n = 8–10 mice. Adverse effects in WEHI-7326 arm: 1 with hind limb paralysis after 4 weeks of treatment. c, d Tumor growth curve (c) and Kaplan–Meier survival plot (d) of AH406 LUSC PDX recipient male mice treated with either docetaxel (10 mg/kg, i.p.; once) or WEHI-7326 (20 mg/kg, i.v.; twice a week). Vehicle mice were administered the vehicle for WEHI-7326. p(docetaxel) = 0.0003 (***), p(WEHI-7326) = 0.0003 (***) compared to vehicle control; p-values obtained through Log-rank (Mantel-Cox) test, n = 6–8 mice.